Abstract
Although percutaneous transluminal coronary intervention has revolutionized the management of patients with coronary artery disease, this technologic advance is neither innocuous nor a panacea. In addition to the technical limitations of the procedure, it is now well recognized that serious vascular injury is caused by the treatment device, which creates an ideal milieu for coronary thrombosis (1–3). Clinical trials of the monoclonal antibody abciximab (c7E3 Fab; ReoProTM, Eli Lilly and Company/Centocor), an agent that blocks the platelet glycoprotein (GP) IIb/IIIa integrin, have clearly documented that inhibition of this receptor during coronary intervention reduces thrombotic complications and improves clinical outcomes (4–8). These positive clinical trial results, coupled with a clearer understanding of platelet physiology, have stimulated the search and encouraged the development of other parenteral inhibitors of the GPIIb/IIIa receptor.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Neuhaus KL, Zeymer U. Prevention and management of thrombotic complications during coronary interventions. Eur Heart J 1995;16(Suppl L):L63—L67.
Wilentz JR, Sanborn TA, Haudenschild CC, et al. Platelet accumulation in experimental angioplasty: time-course and relation to vascular injury. Circulation 1987;76:1225–1234.
Steele PM, Chesebro JH, Stanson AW, et al. Balloon angioplasty: natural history of the pathophysiological response to injury in a pig model. Circ Res 1985;57:105–112.
The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994;330:956–961.
Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin β3 blockade with percutaneous coronary intervention. JAMA 1997; 278:479–484.
The EPILOG Investigators. Platelet glycoprotein receptor blockade and low dose heparin during percutaneous coronary revascularisation. N Engl J Med 1997;336:1689–1696.
Lincoff AM, Tcheng JE, Califf RM, et al. Standard versus low dose weight adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularisation. The PROLOG investigators. Am J Cardiol 1997;79:286–291.
The CAPTURE Investigators. Randomized placebo controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429–1435.
Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553–1559.
Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb/IIIa complex. Blood 1988;71:831–843.
Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/ lIla: a member of a family of Arg-Gly-Asp-specific adhesion receptors. Science 1986;231:1559–1562.
Mustard JF, Kinlough-Rathbone RL, Packham MA. Comparison of fibrinogen association with normal and thrombasthenic platelets on exposure to ADP or chymotrypsin. Blood 1979;54:987–993.
Dennis MS, Henzel WJ, Pitti RM, et al. Platelet glycoprotein IIb/lila protein antagonists from snake venoms: evidence for a family of platelet aggregation inhibitors. (ArgGlyAsp/fibrinogen receptor/ trigramin/echistatin/kistrin). Proc Natl Acad Sci USA 1989;87:2471–2475.
Scarborough RM, Naughton MA, Teng W. Design of potent and specific integrin antagonists with high specificity for glycoprotein IIb/IIIa. J Biol Chem 1993;268:1066–1073.
Charo IF, Scarborough RM, Du Mee CP, et al. Therapeutics I: pharmacodynamics of the glycoprotein IIb/IIIa antagonist integrelin: phase 1 clinical studies in normal healthy volunteers. Circulation 1992;86 (Suppl I):I-260.
Scarborough RM, Rose JW, Hsu MA. Barbourin. A GPIIb/IIIa-specific integrin antagonist from the venom of Sistrurus m barbouri. J Biol Chem 1991;266:9359–9362.
Tcheng JE, Harrington RA, Kottke-Marchant K, et al. Multicenter, randomized, double-blind, placebocontrolled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. Circulation 1995;76:2151–2157.
Harrington RA, Klieman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995;76:1222–1227.
The IMPACT II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II. Lancet 1997;349:1422–1428.
Lincoff AM, Tcheng JE, Ellis SG, et al., for the IMPACT II Investigators. Randomized trial of platelet glycoprotein IIb/IIIa inhibition with Integrelin for prevention of restenosis following coronary intervention: the IMPACT II angiographic substudy. Circ Suppl 1995;92:I-2905.
Phillips DR, Teng W, Arfsten A, et al. Effect of calcium on GP IIb/IIIa interactions with Integrelinenhanced GP IIb/IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997;96:1488–1494.
Tcheng JE. Glycoprotein IIb/IIIa inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol 1996;78(Suppl 3A):35–40.
The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436–443.
Tcheng JE, Talley JD, O’Shea JC, et al. Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). Am J Cardiol 2001;88:1097–1102.
Gilchrist IC, O’Shea JC, Kosoglou T, et al. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation 2001;104:406–411.
O’Shea JC, Hafley GE, Greenberg S, et al. ESPRIT Investigators (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy trial). Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA 2001; 285:2468–2473.
The ESPRIT Investigators. Enhanced suppression of the platelet iib/iiia receptor with integrilin therapy. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. [erratum appears in Lancet 2001 Apr 28;357:1370]. Lancet 2000;356: 2037–2044.
O’Shea JC, Buller CE, Cantor WJ, et al., for the ESPRIT Investigators. Long-term efficacy of platelet glycoprotein IIb/IIIa Integrin blockade with eptifibatide in coronary stent intervention. JAMA 2002; 287:618–621.
Steinhubl SR, Ellis SG, Wolski K, Lincoff AM, Topol EJ. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the evaluation of platelet IIb/IIIa inhibitor for stenting (EPISTENT) trial. Circulation 2001;103:1403–1409.
Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1997;95:809–813.
Ch apter 7
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Deg, JP., O’Shea, J.C., Tcheng, J.E. (2003). Eptifibatide in Coronary Intervention. In: Lincoff, A.M. (eds) Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-376-7_6
Download citation
DOI: https://doi.org/10.1007/978-1-59259-376-7_6
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-408-1
Online ISBN: 978-1-59259-376-7
eBook Packages: Springer Book Archive